Serum levels of fibroblast growth factor-2 distinguish Takayasu arteritis from giant cell arteritis independent of age at diagnosis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 01 2019
Historique:
received: 11 07 2018
accepted: 29 11 2018
entrez: 26 1 2019
pubmed: 27 1 2019
medline: 11 8 2020
Statut: epublish

Résumé

Takayasu arteritis (TAK) and giant cell arteritis (GCA) are two major variants of large vessel vasculitis, and age is a major factor in their differential diagnosis. We sought to determine whether the two diseases exist on the same spectrum. We compared the serum levels of multiple cytokines and chemokines in 25 patients with TAK, 20 patients with GCA, and sex- and age-matched healthy donors for either condition (HD-TAK and HD-GCA). To evaluate the effects of age on the levels of cytokines and chemokines, we performed multiple logistic regression analysis using the least absolute shrinkage and selection operator (LASSO) method. The levels of IL-1RA, IL-10, GM-CSF, G-CSF, FGF-2, eotaxin, and IP-10 were significantly different between TAK and GCA, but no differences were found in the levels of IL-6, IL-12(p40), IL-17, IFN-γ, and TNF-α. Significant differences in the levels of IL-1RA, IL-10, GM-CSF, eotaxin, and IP-10 were observed between the HD-TAK and HD-GCA groups. Multiple logistic regression analysis demonstrated that only FGF-2 and IP-10 could significantly distinguish the diseases when added to age. Multiple logistic analysis using factors selected by the LASSO method revealed that FGF-2 was the only significant factor to distinguish the diseases when added to age. Among numerous cytokines and chemokines analyzed, only FGF-2 could be used together with age at diagnosis to differentiate TAK and GCA. Our results suggested the importance of considering the effects of age on serum cytokines.

Identifiants

pubmed: 30679579
doi: 10.1038/s41598-018-36825-y
pii: 10.1038/s41598-018-36825-y
pmc: PMC6345929
doi:

Substances chimiques

Chemokines 0
Cytokines 0
IP10-Mig receptor 0
Receptors, Cytokine 0
Fibroblast Growth Factor 2 103107-01-3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

688

Références

Am J Pathol. 1999 Sep;155(3):765-74
pubmed: 10487834
Int J Biochem Cell Biol. 2000 Mar;32(3):263-7
pubmed: 10716624
Stat Med. 2002 Aug 30;21(16):2409-19
pubmed: 12210625
Biochem Biophys Res Commun. 2002 Oct 4;297(4):1058-61
pubmed: 12359263
Angiogenesis. 2002;5(1-2):107-10
pubmed: 12549867
Circ Res. 2004 Mar 19;94(5):664-70
pubmed: 14739162
Am J Surg Pathol. 2006 Sep;30(9):1159-68
pubmed: 16931961
Medicine (Baltimore). 2009 Jul;88(4):221-6
pubmed: 19593227
Arthritis Rheum. 1990 Aug;33(8):1129-34
pubmed: 1975175
Curr Opin Rheumatol. 2011 Jan;23(1):43-9
pubmed: 20827207
Arthritis Rheum. 1990 Aug;33(8):1122-8
pubmed: 2202311
Cell Immunol. 2012;273(2):124-32
pubmed: 22316526
Ann Rheum Dis. 2012 Aug;71(8):1329-34
pubmed: 22328740
Arthritis Rheum. 2012 Apr;64(4):943-54
pubmed: 22389040
Clin Exp Immunol. 2012 Nov;170(2):186-93
pubmed: 23039889
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Nature. 1989 Feb 2;337(6206):471-3
pubmed: 2464767
Rheumatology (Oxford). 2015 Mar;54(3):463-70
pubmed: 25193809
J Rheumatol. 2015 Feb;42(2):300-8
pubmed: 25399386
Clin Rheumatol. 2015 Apr;34(4):721-7
pubmed: 25416136
Arthritis Rheumatol. 2015 May;67(5):1353-60
pubmed: 25604824
Autoimmun Rev. 2017 Oct;16(10):1071-1078
pubmed: 28778711
Autoimmun Rev. 2018 Feb;17(2):188-194
pubmed: 29196244
Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):33-39
pubmed: 29600943
J Exp Med. 1995 Jul 1;182(1):155-62
pubmed: 7540647
Int J Cardiol. 1996 Aug;54 Suppl:S155-63
pubmed: 9119518

Auteurs

Shoichi Fukui (S)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. fukui-ngs@umin.ac.jp.
Department of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. fukui-ngs@umin.ac.jp.

Ayako Kuwahara-Takaki (A)

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Nobuyuki Ono (N)

Department of Rheumatology, Saga University, Saga, Japan.

Shuntaro Sato (S)

Nagasaki University Hospital Clinical Research Center, Nagasaki, Japan.

Tomohiro Koga (T)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Shin-Ya Kawashiri (SY)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Nozomi Iwanaga (N)

Department of General Internal Medicine and Rheumatology, Clinical Research Center, NHO Nagasaki Medical Center, Omura, Nagasaki, Japan.

Naoki Iwamoto (N)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Kunihiro Ichinose (K)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Mami Tamai (M)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Hideki Nakamura (H)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Tomoki Origuchi (T)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Kiyoshi Migita (K)

Department of Rheumatology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Yojiro Arinobu (Y)

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Hiroaki Niiro (H)

Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Yoshifumi Tada (Y)

Department of Rheumatology, Saga University, Saga, Japan.

Koichi Akashi (K)

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Takahiro Maeda (T)

Department of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of General Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Atsushi Kawakami (A)

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH